The U.S. Food and Drug Administration (FDA) has granted full approval to the non-nucleoside reverse transcriptase inhibitor (NNRTI) Intelence (etravirine).

Intelence is a second generation NNRTI that works against many strains of HIV that are resistant to other NNRTI’s such as Sustiva (efavirenz) and Viramune (nevirapine).

Intelence is approved for use in people living with HIV who have used and become resistant to other antiretroviral drugs. Intelence was granted conditional approval by the FDA in January 2008, with full approval conditional upon the completion of 48 weeks of two Phase III clinical trials.